Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

23 Apr 2010 15:16

RNS Number : 7219K
Hikma Pharmaceuticals Plc
23 April 2010
 



 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i)

 

3.

Name of person discharging managerial

responsibilities/director

 

BASSAM KANAAN

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

BASSAM KANAAN

8.

State the nature of the transaction

 

SALE OF 30,000 NIL-COST SHARE AWARDS UNDER THE TERMS OF THE 2006 LONG TERM INCENTIVE PLAN UPON VESTING

 

AND

 

EXERCISE OF 43,582 ORDINARY SHARES AT $0.9075 PER SHARE UNDER THE TERMS OF THE 2004 STOCK OPTION PLAN

 

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

 

N/A

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

30,000 (LTIP)

 

43,582 (STOCK OPTIONS)

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

0.0038%

 

13.

Price per share or value of transaction

 

£6.4268998 (LTIP)

 

£6.35 (for 13,582 STOCK OPTIONS)

 

£6.36 (for 30,000 STOCK OPTIONS)

14.

Date and place of transaction

 

22 APRIL 2010, LONDON (LTIP AND 13,582 OF STOCK OPTIONS)

 

23 APRIL (30,000 STOCK OPTIONS)

 

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

89,222 (0.046%)

16.

Date issuer informed of transaction

 

23 APRIL 2010

 

 

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

N/A

18.

Period during which or date on which exercisable

 

 N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

Mark Duckworth 0207 399 2766

 

 

 

 

 

Name of authorised official of issuer responsible for making notification

 

Henry Knowles

 

Date of notification 23 April 2010

 

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBSGDSUBDBGGX
Date   Source Headline
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition
2nd Mar 20214:44 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:01 pmRNSDirector/PDMR Shareholding
25th Feb 20211:00 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSFinal Results
8th Feb 20212:55 pmRNSNotice of Results
26th Jan 20218:01 amRNSPotential Acquisition
15th Jan 20213:59 pmRNSHikma provides update on generic Advair Diskus®
13th Jan 20219:21 amRNSDirector/PDMR Shareholding
13th Jan 20219:14 amRNSDirector/PDMR Shareholding
18th Dec 202010:10 amRNSHolding(s) in Company
17th Dec 20205:30 pmRNSHikma launches generic Advair Diskus®
14th Dec 202012:57 pmRNSHolding(s) in Company
10th Dec 20204:00 pmRNSDirector/PDMR Shareholding
10th Dec 20203:51 pmRNSDirector/PDMR Shareholding
2nd Dec 20203:00 pmRNSTotal Voting Rights
2nd Dec 20201:05 pmRNSHolding(s) in Company
9th Nov 202011:38 amRNSHolding(s) in Company
5th Nov 202011:30 amRNSDirectorate Change
5th Nov 20207:00 amRNSHikma launches Icosapent Ethyl Capsules
5th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:20 pmRNSTotal Voting Rights
22nd Oct 20201:16 pmRNSNotice to Bondholders
8th Oct 20208:38 amRNSBlocklisting Application
1st Oct 202011:01 amRNSBlock listing Interim Review
22nd Sep 20207:00 amRNSHikma updates on ANDA for generic Advair Diskus®
3rd Sep 20203:15 pmRNSHikma receives favourable court ruling
2nd Sep 20209:30 amRNSTotal Voting Rights
7th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20202:25 pmRNSTotal Voting Rights
16th Jul 202012:06 pmRNSNotice of Results
7th Jul 202012:48 pmRNSPublication of Offering Circular
25th Jun 20204:12 pmRNSHolding(s) in Company
25th Jun 20201:00 pmRNSDirectorate Change
23rd Jun 20205:30 pmRNSHikma Pharmaceuticals
23rd Jun 202011:39 amRNSHolding(s) in Company
23rd Jun 20207:00 amRNSTransaction in Own Shares
23rd Jun 20207:00 amRNSResult of placing in Hikma Pharmaceuticals PLC
22nd Jun 20205:13 pmRNSTransaction in Own Shares
22nd Jun 20205:09 pmRNSProposed Placing in Hikma Pharmaceuticals PLC
22nd Jun 202011:24 amRNSDirector/PDMR Shareholding
22nd Jun 202011:22 amRNSDirector/PDMR Shareholding
22nd Jun 202011:20 amRNSDirector/PDMR Shareholding
2nd Jun 20209:31 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.